Mucopolysaccharidosis III-B
1
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
JCR PharmaceuticalsJR-446
JCR PharmaceuticalsJR-446
Abeona TherapeuticsABO-101
Clinical Trials (3)
Total enrollment: 23 patients across 3 trials
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
Start: Jun 2026Est. completion: Sep 202812 patients
Phase 1/2Not Yet Recruiting
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
Start: Nov 2024Est. completion: Apr 203010 patients
Phase 1/2Recruiting
A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101
Start: Oct 2020Est. completion: Apr 20221 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 23 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.